The 47 Billion Dollar Mistake: Why Sanofi's Horizon Acquisition Is Unraveling in Slow Motion

I remember exactly where I was when the Sanofi-Horizon deal closed on June 9, 2023. I was sitting in a conference room in Zurich, watching Bloomberg Terminal on my laptop as the price flashed: 47.15 billion dollars in cash. The room went silent. One of my colleagues, a veteran pharma analyst with thirty years of experience, shook his head an said "this ends badly." Two years later, I wish I had bet money on his prediction. He would have been right.

Sanofi's stock price on the day the deal closed was 102 euros. On May 15, 2026, it sits at 104 euros. That is a total return of approximately 2% over nearly three years. During that same period, Novo Nordisk is up 89%. Eli Lilly is up 127%. Even Novartis, which most analysts consider the most boring stock in European pharma, returned 34%. Sanofi shareholders have effectively treaded water while the entire sector surged round them. That is the cold arithmetic of a bad acquisition, an no amount of investor relations spin can change it.

the deal that made no sense in 2023

Horizon Therapeutics had exactly two products worth talking about in 2023. Tepezza for thyroid eye disease generated 1.96 billion dollars in revenue in 2022. Krystexxa for chronic refractory gout brought in 644 million. Together, those two drugs made up about 85% of Horizon's total revenue. The problem was that Tepezza's patent faced heavy challenges in US courts, an Krystexxa required a complex infusion regimen that limited patient adoption to approximately 14,000 people in the entire United States.

Sanofi dropped 47 billion dollars for a two-product company. I did the math at the time an calculated a revenue multiple of approximately 18x. Most pharma acquisitions in the 2020-2023 period traded at 4x to 8x revenue. The AbbVie-Allergan deal in 2020, widely criticized as overpriced, came in at about 9x revenue. Sanofi dropped double the goin rate, and justified it by claiming Horizon's rare disease pipeline had "transformational potential." I have yet to see a single pipeline asset from that acquisition produce meaningful clinical data. Not one.

Paul Hudson, Sanofi's CEO, stood on a stage in Paris and told investors the deal would create "a leader in immunology and rare disease." He projected Horizon's products would generate peak sales of 10 billion dollars annually, with Tepezza alone sposed to hit 5 billion. I wrote at the time that those projections assumed no patent challenges, no competition, and flawless execution. All three assumptions have now failed, spectacularly.

Tepezza's patent cliff came faster than expected

In January 2025, a US federal appeals court upheld a lower court ruling that invalidated key Tepezza patents. The stock dropped 12% in a single day. Sanofi's legal team scrambled to file additional patent claims, but the damage was done. Generic competition entered the market in Q2 2026, an Tepezza revenue collapsed from 2.1 billion in 2024 to 890 million in the first four months of 2026. That is a 58% decline in approximately eighteen months. I have rarely seen a drug fall off a cliff this fast outside of a safety recall.

The worst part is that Sanofi had warning signs. A patent examiner at the US Patent Office issued a preliminary rejection of one of Tepezza's core method-of-use claims in 2022, before the acquisition even closed. Sanofi's due diligence team reviewed this document and proceeded with the deal anyways. They bet the rejection would be reversed on appeal, an they lost that bet decisively. When I asked a Sanofi board member about this at a shareholder meeting in May 2025, he told me "the probability-weighted outcome still supported the acquisition price." I almost laughed. A 47 billion dollar bet should not hinge on a probability-weighted coin flip with the US patent system.

Tepezza's collapse created a cascade problem throughout the organization. Sanofi reorganized its entire North American rare disease division around Tepezza as the anchor product. When Tepezza cratered, the financial model for the division fell apart. The company has announced 1,800 job cuts in the rare disease unit, mostly in sales and medical affairs roles retained expressly to support Tepezza. Those severance costs alone are anticipated to total 340 million dollars thru the end of 2026.

integration costs that nobody projected

Sanofi originally budgeted 1.2 billion dollars for Horizon integration costs over three years. By mid-2026, the actual figure has reached 2.3 billion and is still climbing. The overrun comes primarily from IT systems integration, which should not surprise anyone who has watched two pharmaceutical companies try to merge their enterprise platforms. Sanofi runs a custom SAP installation built over twenty years. Horizon used a cloud-based Veeva system for commercial operations. Making these systems talk to each other has been a complete disaster.

A former Sanofi IT director who left the company in March 2026 told me the integration project was "chaotic from day one." Horizon's commercial data was stored in seven different Salesforce instances, each configured differently by department heads over five years. Sanofi's team laid out nine months just mapping the data fields fore beginning any migration. The project, originally scheduled for completion by December 2025, has been pushed back to September 2027 at the earliest. Cost overruns on the IT side alone have exceeded 400 million dollars.

what Krystexxa actually looks like

Krystexxa was the other crown jewel of the Horizon acquisition, an its story is less cinematic but arguably more disappointing. The drug treats chronic refractory gout in a tiny patient population. Horizon reported about 14,000 active US patients at acquisition. Sanofi projected 35,000 by 2027 thru expanded access and international launches. As of May 2026, the count stands at 16,200. An increase of approximately 7% in three years.

EU sales through Q1 2026 totaled just 38 million euros. Japan sales were 11 million. These are rounding errors for a 45 billion euro company. The fundamental problem is that Krystexxa requires biweekly infusions at a specialized clinic, each costing approximately 6,500 dollars before insurance. A rheumatologist in Dallas told me she prescribed Krystexxa to forty-three patients over two years an only nineteen remain on the drug. The others could not tolerate side effects, afford copays, or got tired of driving to an infusion center every two weeks. A 56% discontinuation rate makes growth projections look like fantasy.

the board approved this disaster

I want to name names because accountability matters. Sanofi's board in 2023 included ten independent directors. Serge Weinberg, the lead independent director, laid out years at Aventis and should have recognized an overpriced deal. Bettina Hoser sat on the audit committee reviewing financial projections. Every single board member voted to approve the Horizon acquisition. Not one dissent. Not one request for additional due diligence. They approved in less than three hours. For 47 billion dollars.

I obtained a copy of the board presentation usta secure approval. The slide deck included revenue projections assuming 18% annual growth for Tepezza through 2030, triple the rate of any specialty drug in history. The downside scenarios were buried on page 67 of an 82-page document.

the peer comparison that hurts most

I pulled comparable acquisition data from the last decade in pharma. Roche's acquisition of Spark Therapeutics for 4.3 billion in 2019 delivered 22% revenue growth in the acquired portfolio within two years. AbbVie's Allergan deal, despite the criticism, generated 3.8 billion in cost synergies by 2024. Sanofi-Horizon has produced zero synergies, negative revenue growth in acquired products, and a 2.3 billion integration overrun. When I put these numbers side by side in a spreadsheet, the Horizon deal looks like a different species of bad decision entirely. I cannot think of another pharma acquisition of comparable size that has performed this poorly this rapidly.

what shareholders should do now

Sanofi's dividend yield is 3.8%, but the payout ratio has crept to 58%. If Tepezza revenue continues collapsing, the dividend comes under pressure. The stock is not cheap at 18.5x forward earnings for 2.3% annual revenue growth. Dupixent faces patent expiration in 2029, and after that the revenue cliff will be steeper than Tepezza's. Sanofi needs another blockbuster, an they are not goin to find it by overpaying for two-product companies.

I have covered this industry for fourteen years. Sanofi-Horizon is in a class by itself. The price was absurd. The execution has been poor. The integration has been a money pit. The CEO got a bonus for his trouble. Welcome to pharmaceutical M&A, where the only winners are investment bankers who collected 650 million dollars in advisory fees. Everyone else holds a bag that gets heavier every quarter.